1210-33-9

Basic information

• Product Name: DIBENZOSUBERYL CHLORIDE
• Synonyms: d)cycloheptene,10,11-dihydro-5-chloro-5h-dibenzo(;5-CHLORO-10,11-DIHYDRO-5H-DIBENZO[A,D]CYCLOHEPTENE;5-CHLORODIBENZOSUBERANE;DIBENZOSUBERYL CHLORIDE;5-Chlorodibenzosuberane~5-Chloro-10,11-dihydro-5H-dibenzo[a,d]cycloheptene;5-CHLOROBENZOSUBERANE;10,11-Dihydro-5-chloro-5H-dibenzo[a,d]cycloheptene;5-Chloro-2,3:6,7-dibenzosuberane
• CAS NO: 1210-33-9
• Molecular Formula: C₁₅H₁₃Cl
• Molecular Weight: 228.72
• EINECS: 214-910-2
• Product Categories: Protection & Derivatization Reagents (for Synthesis);Synthetic Organic Chemistry;Alkyl;Building Blocks;Chemical Synthesis;Halogenated Hydrocarbons;Organic Building Blocks
• Mol File: 1210-33-9.mol

Chemical Properties

• Melting Point: 106-107 °C(lit.)
• Boiling Point: 321.7°Cat760mmHg
• Flash Point: 136.6°C
• Appearance: /
• Density: 1.19g/cm³
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.627
• Storage Temp.: Inert atmosphere,Room Temperature
• Solubility: Chloroform (Slightly), Ethyl Acetate (Slightly)
• Sensitive: Moisture Sensitive
• Stability: Light Sensitive
• BRN: 612280
• CAS DataBase Reference: DIBENZOSUBERYL CHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: DIBENZOSUBERYL CHLORIDE(1210-33-9)
• EPA Substance Registry System: DIBENZOSUBERYL CHLORIDE(1210-33-9)

Safety Data

• Hazard Codes: 34:
• Statements: 34
• Safety Statements: 26-36/37/39-45
• RIDADR: 3261
• WGK Germany: 3
• RTECS: HO8302000
• HazardClass: 8
• PackingGroup: II
• Hazardous Substances Data: 1210-33-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Dibenzosuberyl Chloride is used as a reagent for the introduction of the 5-dibenzosuberyl moiety in the development of anticancer drugs. This moiety serves as a modulator, enhancing the effectiveness of these drugs in combating cancer.
Used in Neuropharmacology:
In the synthesis of atypical tricyclic antidepressants, Dibenzosuberyl Chloride is used as a key component. These antidepressants are designed to treat mood disorders by modulating the levels of neurotransmitters in the brain.
Used in Neurobiology:
Dibenzosuberyl Chloride is used in the synthesis of dibenzosuberyl-substituted tropines, which act as ligands for acetylcholine-binding protein. These ligands are crucial for studying the function and regulation of acetylcholine receptors, which play a significant role in the nervous system.
Used in Peptide Synthesis:
Dibenzosuberyl Chloride is utilized in the preparation of amino protecting groups for solid-phase peptide synthesis. These protecting groups are essential for the stepwise assembly of peptides, ensuring the correct sequence and preventing unwanted side reactions during the synthesis process.

InChI:InChI=1/C15H13Cl/c16-15-13-7-3-1-5-11(13)9-10-12-6-2-4-8-14(12)15/h1-8,15H,9-10H2

Upstream product

• 1210-34-0 dibenzosuberol 
• 1210-35-1 10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-one 
• 4890-85-1 o-phenethylbenzoic acid 

Downstream Products

• 59188-82-8 N-Dibenzosuberyl-2-(4-methoxyphenyl)-ethylamin 
• 1729-63-1 10,11-dihydro-5H-dibenzo[a,d]cycloheptene-5-carbonitrile 
• 59188-97-5 (S)-2-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylamino)-3-phenyl-propionic acid 10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl ester 
• 69159-50-8 1-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)piperazine 
• 4821-67-4 4-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-N,N-dimethyl-aniline 
• 68101-79-1 [4-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylamino)-phenyl]-acetonitrile 
• 68101-80-4 (2,6-Diethyl-phenyl)-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amine 
• 68101-77-9 (10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-(2-ethyl-6-methyl-phenyl)-amine 
• 68101-82-6 2-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylamino)-3-methyl-benzoic acid methyl ester 
• 68101-81-5 (10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-(2,6-diisopropyl-phenyl)-amine 
• 68101-76-8 (10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-(2,6-dimethyl-phenyl)-amine 
• 68101-78-0 (10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-(2-methoxy-6-methyl-phenyl)-amine 
• 824396-57-8 N-[6-cyclohexyloxy-8-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yloxy)-2-styryl-hexahydro-pyrano[3,2-d][1,3]dioxin-7-yl]-acetamide 
• 824396-58-9 N-[8-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yloxy)-6-dodecyloxy-2-styryl-hexahydro-pyrano[3,2-d][1,3]dioxin-7-yl]-acetamide 

Relevant articles and documents

The second aryl piperazine compounds and their pharmaceutical use (by machine translation)

The invention relates to the general formula I indicated by the two aryl piperazine compound, solvate, stereoisomer or a pharmaceutically acceptable salt thereof, pharmaceutical compositions containing them, and the compounds for the preparation for preventing or treating post-surgical pain, migraine, visceral pain, neuropathic pain such as the pain and analgesics such as by analgesic drug addiction and tolerance caused by the use of disease. (by machine translation)

Dibenzo[b,f][1,4]oxazepines and dibenzo[b,e]oxepines: Influence of the chlorine substitution pattern on the pharmacology at the H1R, H4R, 5-HT2AR and other selected GPCRs

Inspired by VUF6884 (7-Chloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepine), reported as a dual H1/H4 receptor ligand (pKi: 8.11 (human H1R (hH1R)), 7.55 (human H4R (hH4R))), four known and 28 new oxazepine and related oxepine derivatives were synthesised and pharmacologically characterized at histamine receptors and selected aminergic GPCRs. In contrast to the oxazepine series, within the oxepine series, the new compounds showed high affinity to the hH1R (pKi: 6.8–8.7), but no or moderate affinity to the hH4R (pKi: ≤ 5.3). For one oxepine derivative (1-(2-Chloro-6,11-dihydrodibenzo[b,e]oxepin-11-yl)-4-methylpiperazine), the enantiomers were separated and the R-enantiomer was identified as the eutomer at the hH1R (pKi: 8.83 (R), 7.63 (S)) and the guinea-pig H1R (gpH1R) (pKi: 8.82 (R), 7.41 (S)). Molecular dynamic studies suggest that the tricyclic core of the compounds is bound in a similar mode into the binding pocket, as described for doxepine in the hH1R crystal structure. Moreover, docking studies of all oxepine derivatives at the hH1R indicate that the oxygen and the position of the chlorine in the tricyclic core determines, if the R- or the S-enantiomer is the eutomer. For some of the oxazepines and oxepines the affinity to other aminergic GPCRs is in the same range as to hH1R or hH4R, thus, those compounds have to be classified as dirty drugs. However, one oxazepine derivative (3,7-Dichloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepine was identified as dual hH1/h5-HT2A receptor ligand (pKi: 9.23 (hH1R), 8.74 (h5-HT2AR), ≤7 at other analysed GPCRs), whereas one oxepine derivative (1-(3,8-Dichloro-6,11-dihydrodibenzo[b,e]oxepin-11-yl)-4-methylpiperazine) was identified as selective hH1R antagonist (pKi: 8.44 (hH1R), ≤6.7 at other analyzed GPCRs). Thus, the pharmacological results suggest that the oxazepine/oxepine moiety and additionally the chlorine substitution pattern toggles receptor selectivity and specificity.

Protease inhibitors: Synthesis of bacterial collagenase and matrix metalloproteinase inhibitors incorporating arylsulfonylureido and 5-dibenzo-suberenyl/suberyl moieties

Novel matrix metalloproteinase (MMP)/bacterial collagenase inhibitors are reported, considering the sulfonylated amino acid hydroxamates as lead molecules. A series of compounds was prepared by reaction of arylsulfonyl isocyanates with N-(5H-dibenzo[a,d]cyclohepten-5-yl)- and N-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl) methyl glycocolate, respectively, followed by the conversion of the COOMe to the carboxylate/hydroxamate moieties. The corresponding derivatives with methylene and ethylene spacers between the polycyclic moiety and the amino acid functionality were also obtained by related synthetic strategies. These new compounds were assayed as inhibitors of MMP-1, MMP-2, MMP-8 and MMP-9, and of the collagenase isolated from Clostridium histolyticum (ChC). Some of the new derivatives reported here proved to be powerful inhibitors of the four MMPs mentioned above and of ChC, with activities in the low nanomolar range for some of the target enzymes, depending on the substitution pattern at the sulfonylureido moiety and on the length of the spacer through which the dibenzosuberenyl/suberyl group is connected with the rest of the molecule. Several of these inhibitors also showed selectivity for the deep pocket enzymes (MMP-2, MMP-8 and MMP-9) over the shallow pocket ones MMP-1 and ChC.

Anti-viral method

PCT No. PCT/US97/07431 Sec. 371 Date Jan. 6, 1999 Sec. 102(e) Date Jan. 6, 1999 PCT Filed May 2, 1997 PCT Pub. No. WO97/41846 PCT Pub. Date Nov. 13, 1997The present invention provides compounds which inhibit an envelope virus by inhibiting the fusion of the virus with the host cell. The virus may be inhibited in an infected cell, a cell susceptible of infection or a mammal in need thereof.

Urea, thiourea and guanidine compounds and their use as anti-viral agents

The present invention provides compounds which inhibit an envelope virus by inhibiting the fusion of the virus with the host cell. The virus may be inhibited in an infected cell, a cell susceptible of infection or a mammal in need thereof.

TRICYCLIC ANALOGUES OF THE ANTIALLERGIC AGENT OXATOMIDE: 1-(3-(4-(10,11-DIHYDRO-5H-DIBENZOCYCLOHEPTENE-5-YL)-1-PIPERAZINYL)PROPYL)-1,3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE AND THE RELATED 6,11-DIHYDRODIBENZOTHIEPIN, 4,9-DIHYDROTHIENO-2-BENZOTHIEPIN, AND ...

11-Chloro-6,11-dihydrodibenzothiepin and its 2-methyl derivative VI were transformed via the 11-(4-(ethoxycarbonyl)-1-piperazinyl) compounds IVc and Vc to 11-(1-piperazinyl) compounds IVb and Vb.Their reactions with 1-(3-chloropropyl)-1,3-dihydro-2H-benzimidazol-2-one (II) afforded the title compounds IVa and IVb.Similar reactions and sequences in the series of 10,11-dihydro-5H-dibenzocycloheptene, 4,9-dihydrothieno-2-benzothiepin, and 10,11-dihydrodibenzothiepin led to further oxatomide (Ia) analogues IIIa and VIIa-XIa.In the test of passivecutaneous anaphylaxis in rats, compound VIIIa was more active than Ia, and IVa had similar activity like Ia.

CYCLOHEPTENE DERIVATIVES

1-2-(4,5,10,11-Tetrahydro-1H-dibenzo a,d!cyclohepten-5-yl) ethyl!pyrrolidine of the formula STR1 and its pharmaceutically acceptable acid addition salts, prepared through various intermediates, are described. The compounds have valuable histamine-H 1 antagonistic properties and are suitable for the control or prevention of allergic reactions, such as, urticaria, hay fever, anaphylaxis and over-sensitivity to medicaments.